Characteristics of patients according to deletion-1p32 status
| . | Patients with del(1p32) . | Patients without del(1p32) . | P value . |
|---|---|---|---|
| Patients, n | 282 | 2269 | |
| Age at diagnosis, mean (SD), y | 63.8 (10.8) | 63.6 (10.7) | .9876 |
| Sex, n (%) | .6655 | ||
| Male | 169 (59.9) | 1323 (58.4) | |
| Female | 113 (40.1) | 943 (41.6) | |
| Missing | 0 | 3 | |
| ISS, n (%) | .0177 | ||
| 1 | 48 (21.7) | 540 (29.2) | |
| 2 | 94 (42.5) | 795 (42.9) | |
| 3 | 79 (35.7) | 517 (27.9) | |
| Patients, n | 221 | 1852 | |
| Missing, n | 61 | 417 | |
| Del(17p), n (%) | <.0001 | ||
| No | 217 (77.5) | 2064 (91.2) | |
| Yes | 63 (22.5) | 199 (8.8) | |
| Missing | 2 | 6 | |
| t(4;14), n (%) | .8478 | ||
| No | 245 (88.4) | 1966 (87.8) | |
| Yes | 32 (11.6) | 272 (12.2) | |
| Missing | 5 | 31 | |
| Gain(1q), n (%) | <.0001 | ||
| No | 127 (45.0) | 1502 (66.2) | |
| Yes | 155 (55.0) | 766 (33.8) | |
| Missing | 0 | 1 | |
| t(14;16), n (%) | .0016 | ||
| No | 91 (87.5) | 689 (95.6) | |
| Yes | 13 (12.5) | 32 (4.4) | |
| Missing | 178 | 1,548 | |
| t(14;20), n (%) | .6969 | ||
| No | 67 (98.5) | 301 (96.8) | |
| Yes | 1 (1.5) | 10 (3.2) | |
| Missing | 214 | 1,958 | |
| TP53mutation, n (%) | .0010 | ||
| No | 55 (72.4) | 288 (88.1) | |
| Yes | 21 (27.6) | 39 (11.9) | |
| Missing | 206 | 1,942 | |
| Hyperdiploidy (>50 chromosomes), n (%) | .0065 | ||
| No | 188 (69.9) | 1336 (61.1) | |
| Yes | 81 (30.1) | 849 (38.9) | |
| Missing | 13 | 84 | |
| First-line therapy, n (%) | |||
| Patients eligible for transplant | |||
| IMiD or PI without anti-CD38 | 20 (14.9) | 178 (15.8) | .1061 |
| Triplet∗ | 104 (77.6) | 905 (80.6) | |
| Triplet + anti-CD38 | 10 (7.5) | 41 (3.6) | |
| Patients not eligible for transplant | |||
| IMiD or PI without anti-CD38 | 84 (59.2) | 716 (64.0) | .0819 |
| IMiD or PI with anti-CD38 | 11 (7.7) | 41 (3.7) | |
| Triplet | 44 (31.0) | 350 (31.3) | |
| Triplet + anti-CD38 | 3 (2.1) | 12 (1.0) | |
| Missing | 6 | 26 | |
| Maintenance therapy for patients eligible for transplant, n (%) | .3161 | ||
| No | 77 (57.5) | 696 (61.9) | |
| Yes | 57 (42.5) | 428 (38.1) | |
| Missing | 0 | 0 |
| . | Patients with del(1p32) . | Patients without del(1p32) . | P value . |
|---|---|---|---|
| Patients, n | 282 | 2269 | |
| Age at diagnosis, mean (SD), y | 63.8 (10.8) | 63.6 (10.7) | .9876 |
| Sex, n (%) | .6655 | ||
| Male | 169 (59.9) | 1323 (58.4) | |
| Female | 113 (40.1) | 943 (41.6) | |
| Missing | 0 | 3 | |
| ISS, n (%) | .0177 | ||
| 1 | 48 (21.7) | 540 (29.2) | |
| 2 | 94 (42.5) | 795 (42.9) | |
| 3 | 79 (35.7) | 517 (27.9) | |
| Patients, n | 221 | 1852 | |
| Missing, n | 61 | 417 | |
| Del(17p), n (%) | <.0001 | ||
| No | 217 (77.5) | 2064 (91.2) | |
| Yes | 63 (22.5) | 199 (8.8) | |
| Missing | 2 | 6 | |
| t(4;14), n (%) | .8478 | ||
| No | 245 (88.4) | 1966 (87.8) | |
| Yes | 32 (11.6) | 272 (12.2) | |
| Missing | 5 | 31 | |
| Gain(1q), n (%) | <.0001 | ||
| No | 127 (45.0) | 1502 (66.2) | |
| Yes | 155 (55.0) | 766 (33.8) | |
| Missing | 0 | 1 | |
| t(14;16), n (%) | .0016 | ||
| No | 91 (87.5) | 689 (95.6) | |
| Yes | 13 (12.5) | 32 (4.4) | |
| Missing | 178 | 1,548 | |
| t(14;20), n (%) | .6969 | ||
| No | 67 (98.5) | 301 (96.8) | |
| Yes | 1 (1.5) | 10 (3.2) | |
| Missing | 214 | 1,958 | |
| TP53mutation, n (%) | .0010 | ||
| No | 55 (72.4) | 288 (88.1) | |
| Yes | 21 (27.6) | 39 (11.9) | |
| Missing | 206 | 1,942 | |
| Hyperdiploidy (>50 chromosomes), n (%) | .0065 | ||
| No | 188 (69.9) | 1336 (61.1) | |
| Yes | 81 (30.1) | 849 (38.9) | |
| Missing | 13 | 84 | |
| First-line therapy, n (%) | |||
| Patients eligible for transplant | |||
| IMiD or PI without anti-CD38 | 20 (14.9) | 178 (15.8) | .1061 |
| Triplet∗ | 104 (77.6) | 905 (80.6) | |
| Triplet + anti-CD38 | 10 (7.5) | 41 (3.6) | |
| Patients not eligible for transplant | |||
| IMiD or PI without anti-CD38 | 84 (59.2) | 716 (64.0) | .0819 |
| IMiD or PI with anti-CD38 | 11 (7.7) | 41 (3.7) | |
| Triplet | 44 (31.0) | 350 (31.3) | |
| Triplet + anti-CD38 | 3 (2.1) | 12 (1.0) | |
| Missing | 6 | 26 | |
| Maintenance therapy for patients eligible for transplant, n (%) | .3161 | ||
| No | 77 (57.5) | 696 (61.9) | |
| Yes | 57 (42.5) | 428 (38.1) | |
| Missing | 0 | 0 |
IMiDs, immunomodulatory drugs; ISS, International Staging System; PI, proteasome inhibitors; SD, standard deviation.
Triplet is defined by the association of 1 IMiD, 1 PI, and 1 corticosteroid (mostly dexamethasone).